<DOC>
	<DOCNO>NCT02008058</DOCNO>
	<brief_summary>This single-arm observational longitudinal study patient metastatic castrate-resistant prostate cancer design ass longitudinal trajectory pain symptom .</brief_summary>
	<brief_title>Observational Longitudinal Study Pain Men With Metastatic Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>This single-arm observational longitudinal study patient metastatic castrate-resistant prostate cancer design ass longitudinal trajectory pain symptom . The study aim address several key methodological question inform design future clinical trial symptom endpoint population , include : definition `` clinically meaningful '' pain ; criterion conclude clinically meaningful pain reduction ; criterion conclude clinically meaningful pain progression ; reliable method quantify analgesic use ( give `` equianalgesic table '' `` point score system '' generally consider unreliable pain researcher regulatory agency , , ) ; ideal recall period pain question ; tradeoff different frequency symptom reporting ; symptom trajectory time ; association pain score metric use prostate cancer research ( image , PSA value , circulate tumor cell , etc ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>The subject must â‰¥ 18 year old day consent . The subject able understand write spoken English The patient must histologically cytologically confirm prostate adenocarcinoma . The subject must castrationresistant prostate cancer ( CRPC ) The subject must metastatic disease involve bone , see radiographic imaging ( bone scan , CT scan , PET scan , MRI ) . The subject must castrate state ( e.g. , currently receive androgen deprivation therapy orchiectomy ) . The subject must start line treatment postandrogen deprivation/antiandrogen therapy , follow : chemotherapy ( e.g. , docetaxel , paclitaxel , carboplatin , cabazitaxel , mitoxantrone ) ; abiraterone acetate ; MDV3100 ; ketoconazole ; sipuleucelT ; Radium 223 . The subject own regular access telephone ( cellular land line ) . The subject willing able selfreport pain analgesic use via automate telephone system . The subject willing able provide inform consent . The subject small cell predominantly neuroendocrine differentiate prostate tumor .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Castrate-Resistant Prostate Cancer</keyword>
	<keyword>LCCC 1231</keyword>
	<keyword>Lineberger Comprehensive Cancer Center</keyword>
	<keyword>UNC Lineberger</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Pain</keyword>
</DOC>